Arthur F Kavanaugh

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, Immunology, University of California, San Diego, La Jolla, California, USA
    Ann Rheum Dis 72:1777-85. 2013
  2. pmc Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
    Stephanie Hennigan
    Division of Rheumatology, Allergy, Immunology, The University of California, San Diego, CA, USA
    Ther Clin Risk Manag 4:767-75. 2008
  3. pmc Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
    Stephanie Hennigan
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, La Jolla, California, USA
    Core Evid 2:295-305. 2008
  4. ncbi request reprint Psoriatic arthritis: treat-to-target
    Arthur Kavanaugh
    University of California, San Diego 92093 0943, USA
    Clin Exp Rheumatol 30:S123-5. 2012
  5. pmc Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
    Arthur Kavanaugh
    UCSD, UCSD, Rheumatology, Allergy, Immunology, La Jolla, CA, USA
    Ann Rheum Dis 72:64-71. 2013
  6. doi request reprint Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, 9500 Gilman Drive, Room A 112, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 64:2504-17. 2012
  7. doi request reprint Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL)
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, Immunology, University of California San Diego, La Jolla, California 92093 0943, USA
    J Rheumatol Suppl 89:90-3. 2012
  8. pmc Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study
    Mari Hoff
    Department of Rheumatology, St, Olavs Hospital, 7006 Trondheim, Norway
    BMC Musculoskelet Disord 12:54. 2011
  9. pmc Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
  10. pmc Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
    Sanna Rosengren
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Arthritis Res Ther 10:R105. 2008

Detail Information

Publications95

  1. pmc Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, Immunology, University of California, San Diego, La Jolla, California, USA
    Ann Rheum Dis 72:1777-85. 2013
    ..To assess long-term golimumab efficacy/safety in patients with active psoriatic arthritis (PsA)...
  2. pmc Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
    Stephanie Hennigan
    Division of Rheumatology, Allergy, Immunology, The University of California, San Diego, CA, USA
    Ther Clin Risk Manag 4:767-75. 2008
    ....
  3. pmc Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
    Stephanie Hennigan
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, La Jolla, California, USA
    Core Evid 2:295-305. 2008
    ..Limited economic evidence suggests that adalimumab 40 mg may be cost effective when used according to current valid treatment guidelines. PLACE IN THERAPY: Adalimumab is an effective treatment for patients with active AS...
  4. ncbi request reprint Psoriatic arthritis: treat-to-target
    Arthur Kavanaugh
    University of California, San Diego 92093 0943, USA
    Clin Exp Rheumatol 30:S123-5. 2012
    ..Therefore, developing a treat-to-target strategy in PsA will require additional disease specific considerations to optimise its implementation...
  5. pmc Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
    Arthur Kavanaugh
    UCSD, UCSD, Rheumatology, Allergy, Immunology, La Jolla, CA, USA
    Ann Rheum Dis 72:64-71. 2013
    ..2 at weeks 22 and 26) and clinical, radiographic and functional outcomes in methotrexate-naive patients with early rheumatoid arthritis (RA)...
  6. doi request reprint Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, 9500 Gilman Drive, Room A 112, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 64:2504-17. 2012
    ..Herein we report 1-year clinical, radiographic, and safety findings...
  7. doi request reprint Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL)
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, Immunology, University of California San Diego, La Jolla, California 92093 0943, USA
    J Rheumatol Suppl 89:90-3. 2012
    ..To assess longer-term outcomes, including enthesitis and dactylitis, in patients with active psoriatic arthritis (PsA), in a study of golimumab treatment...
  8. pmc Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study
    Mari Hoff
    Department of Rheumatology, St, Olavs Hospital, 7006 Trondheim, Norway
    BMC Musculoskelet Disord 12:54. 2011
    ..The objective of this study was to examine if treatment with the TNF-α inhibitor adalimumab also could reduce periarticular bone loss in RA patients independent of disease activity...
  9. pmc Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
    ..The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA)...
  10. pmc Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
    Sanna Rosengren
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Arthritis Res Ther 10:R105. 2008
    ....
  11. pmc The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, Pennsylvania 19355, USA
    Arthritis Res Ther 9:R103. 2007
    ..Patients in large randomized controlled studies of infliximab in RA, PsA, and AS had similar impairment in physical aspects of HRQoL at baseline and showed significantly greater improvement in HRQoL after treatment with infliximab...
  12. doi request reprint Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, San Diego, CA, USA
    Curr Med Res Opin 26:2385-92. 2010
    ....
  13. ncbi request reprint Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, San Diego, CA 92037 0943, USA
    J Rheumatol 30:449-54. 2003
    ..AG4263 is a soluble complex of native HLA-DR4 (beta*0401) complexed to Org 36601, a 13-mer peptide derived from HC gp-39 (also referred to as CDP263)...
  14. doi request reprint Patient-derived joint counts are a potential alternative for determining Disease Activity Score
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92037 0943, USA
    J Rheumatol 37:1035-41. 2010
    ..To investigate the correlation between the Disease Activity Score using a 28-joint count (DAS28) based on physician-derived joint counts and the DAS28 based on patient-derived joint counts (Pt-DAS28) in rheumatoid arthritis (RA)...
  15. ncbi request reprint Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
    Arthur Kavanaugh
    Center for Innovative Therapy, University of California, San Diego, Division of Rheumatology, Allergy and Immunology, 9500 Gilman Drive, Mail Code 0943, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 61:1592-600. 2009
    ....
  16. doi request reprint Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
    Arthur Kavanaugh
    University of California, San Diego, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 60:976-86. 2009
    ..To assess the efficacy and safety of golimumab in patients with active psoriatic arthritis (PsA)...
  17. ncbi request reprint Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA
    J Rheumatol 33:2254-9. 2006
    ..To examine the effect of infliximab on employment status, time lost from work, and productivity in a double-blind, placebo-controlled study of patients with active psoriatic arthritis (PsA)...
  18. doi request reprint Infection prophylaxis in antirheumatic therapy: emphasis on vaccination
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California 92093 0943, USA
    Curr Opin Rheumatol 21:419-24. 2009
    ..To assess data concerning vaccination among persons with rheumatic diseases, focusing on the effects of immune-modulating therapeutic agents on the responses...
  19. doi request reprint Therapy: Guidelines in rheumatology: quo vadis?
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Nat Rev Rheumatol 5:423-4. 2009
    ..The implementation of evidence-based guidelines designed to inform clinicians' decisions requires careful consideration of several important issues...
  20. ncbi request reprint Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California at San Diego, La Jolla, California 92093, USA
    J Rheumatol 31:849-55. 2004
    ..We also assessed the influence of improvement in physical function on employability, healthcare costs, and quality of life, utilizing data collected in the ATTRACT trial...
  21. ncbi request reprint Outcome measures in psoriatic arthritis
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Curr Rheumatol Rep 7:195-200. 2005
    ..To date, such measures have largely been adapted from other similar diseases. With further research, the most appropriate outcome measures specific for PsA will be delineated...
  22. pmc Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results
    A Kavanaugh
    University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, 9500 Gilman Drive, Mail Code 0943, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 67:402-8. 2008
    ..Marked depletion of circulating B cells, seen in almost all patients, does not correlate with efficacy. The potential synovial immunomodulatory effects of rituximab have not been fully defined...
  23. ncbi request reprint Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, The University of California at San Diego, La Jolla, California 92093 0943, USA
    Bull NYU Hosp Jt Dis 65:S16-20. 2007
    ..Data from studies currently underway will help refine the ultimate use of this novel approach to treatment, and help clinicians optimize therapy using this approach...
  24. ncbi request reprint Economic consequences of established rheumatoid arthritis and its treatment
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92093 0943, USA
    Best Pract Res Clin Rheumatol 21:929-42. 2007
    ..Therefore, it is appropriate for pharmacoceconomic analyses to take into account all relevant costs, not only of the treatments, but of the disease itself. In this way, the value of therapies can be correctly estimated...
  25. ncbi request reprint Quality indicators in psoriatic arthritis
    A Kavanaugh
    University of California at San Diego, San Diego, CA, USA
    Clin Exp Rheumatol 25:98-101. 2007
    ..As such, these guidelines will form the basis for identifying what constitutes quality medical care for patients with PsA...
  26. ncbi request reprint Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis
    Arthur Kavanaugh
    The Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, California 92093 0943, USA
    Curr Opin Rheumatol 18:347-53. 2006
    ..The greatest experience has accrued in ankylosing spondylitis and psoriatic arthritis. This paper reviews data from clinical trials with tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis...
  27. pmc Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA, and University Hospital Leuven, Belgium
    Ann Rheum Dis 66:498-505. 2007
    ..To evaluate the efficacy and safety of infliximab through 1 year in patients with psoriatic arthritis (PsA) enrolled in the IMPACT 2 trial...
  28. pmc Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 65:471-7. 2006
    ..To evaluate the effect of infliximab on health related quality of life (HRQoL) and physical function in patients with active psoriatic arthritis (PsA) in the IMPACT 2 trial...
  29. pmc Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 64:ii46-8. 2005
    ..Because of these developments, there is a need to continually assess the design of current and future research studies so that they may be conducted in the optimal and most ethical manner...
  30. ncbi request reprint Combination cytokine therapy: the next generation of rheumatoid arthritis therapy?
    Arthur Kavanaugh
    The University of California, San Diego, USA
    Arthritis Rheum 47:87-92. 2002
  31. ncbi request reprint Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093, USA
    Nat Clin Pract Rheumatol 2:346-7. 2006
  32. pmc Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, UCSD, San Diego, California, USA
    Ann Rheum Dis 67:1444-7. 2008
    ..Whereas many patients respond quickly to treatment with tumour necrosis factor (TNF) inhibitors, some patients may experience significant but delayed responses...
  33. ncbi request reprint Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests
    Arthur F Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, San Diego, CA 92037, USA
    Arthritis Rheum 47:546-55. 2002
  34. ncbi request reprint B cell targeted therapies: safety considerations
    Arthur F Kavanaugh
    Center for Innovative Therapy, University of California San Diego, San Diego, California 92093 0943, USA
    J Rheumatol Suppl 77:18-23. 2006
    ....
  35. ncbi request reprint Defining remission in psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Clin Exp Rheumatol 24:S-83-7. 2006
    ..In this paper we present a number of key principles and considerations critical to laying the groundwork for defining remission in PsA...
  36. pmc The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year
    A Kavanaugh
    Center for Innovative Therapy, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 65:1038-43. 2006
    ..Using IMPACT trial data, we assessed the effect of infliximab (IFX) on structural damage in PsA...
  37. ncbi request reprint The assessment of disease activity and outcomes in psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Clin Exp Rheumatol 23:S142-7. 2005
    ..To date, such measures have largely been adapted from related diseases, as described in this essay. Further research is needed to further develop outcome measures for PsA to facilitate optimal treatment of patients with PsA...
  38. ncbi request reprint Economic issues with new rheumatologic therapeutics
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Curr Opin Rheumatol 19:272-6. 2007
    ..Brought to the clinic initially for the treatment of rheumatoid arthritis, biologic agents have found expanded indication in other rheumatic diseases...
  39. ncbi request reprint The pharmacoeconomics of newer therapeutics for rheumatic diseases
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, La Jolla, CA 92093 0943, USA
    Rheum Dis Clin North Am 32:45-56, viii. 2006
    ..This issue has been analyzed in greatest detail in rheumatoid arthritis. Increasing data suggest that newer therapeutics may be cost-effective for rheumatoid arthritis and other rheumatic diseases...
  40. pmc Health economics: implications for novel antirheumatic therapies
    A Kavanaugh
    Center for Innovative Therapy and Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 64:iv65-9. 2005
    ..This paper discusses the pharmacoeconomics issues relating to the use of the newer therapies for rheumatoid arthritis (RA), namely the tumour necrosis factor (TNF) inhibitors...
  41. pmc Minimally important differences of the gout impact scale in a randomized controlled trial
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, University of California at San Diego, La Jolla, CA 90095, USA
    Rheumatology (Oxford) 50:1331-6. 2011
    ..Our objective was to assess minimally important differences (MIDs) for the GIS administered in a randomized controlled trial (RCT) assessing rilonacept vs placebo for prevention of gout flares during initiation of allopurinol therapy...
  42. doi request reprint Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis
    Jeremy Sokolove
    Stanford University, Palo Alto, CA, USA
    Ann Rheum Dis 69:1612-7. 2010
    ....
  43. doi request reprint Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008
    Christopher T Ritchlin
    Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol 37:462-7. 2010
    ..The appearance of new therapeutic options in PsA raises the need for sensitive biomarkers for both disease activity and outcome...
  44. doi request reprint Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment
    Andrew J Sarkin
    Health Services Research Center, University of California, San Diego, California, USA
    J Eval Clin Pract 16:1244-7. 2010
    ....
  45. ncbi request reprint Therapies for psoriatic nail disease. A systematic review
    Sarah Cassell
    Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, La Jolla, California 92093 0943, USA
    J Rheumatol 33:1452-6. 2006
    ..The lack of standardized outcome assessments hinders the interpretation of available data. In this systematic evidence-based review of the literature, we assess various treatments for psoriatic nail disease...
  46. ncbi request reprint Secondary immune deficiencies associated with biological therapeutics
    Susan J Lee
    Division of Rheumatology, Allergy and Immunology, Center for Innovative Therapy, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Curr Allergy Asthma Rep 3:389-95. 2003
    ..Both clinical and in vitro studies have been done to explore the potential immunomodulatory and immunosuppressive effects of these agents...
  47. ncbi request reprint Recent developments in diet and gout
    Susan J Lee
    Center for Innovative Therapy, University of San Diego, La Jolla, California 92037, USA
    Curr Opin Rheumatol 18:193-8. 2006
    ..This review focuses on recent developments and their implications for clinical practice, including how we advise patients on appropriate diets and alcoholic beverage consumption...
  48. ncbi request reprint Evaluation of an instrument assessing influence of Gout on health-related quality of life
    Jan D Hirsch
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093 0714, USA
    J Rheumatol 35:2406-14. 2008
    ..To evaluate the reliability and validity of an instrument assessing the influence of gout (acute and chronic) on health-related quality of life (HRQOL)...
  49. ncbi request reprint Electronic and computer-generated patient questionnaires in standard care
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, 9320 Campus Point Dr Suite 225, Mailcode 0943, La Jolla, CA 92037 0943, USA
    Best Pract Res Clin Rheumatol 21:637-47. 2007
    ....
  50. doi request reprint Biologic therapy for early rheumatoid arthritis: the latest evidence
    Hernan Castro-Rueda
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, California, USA
    Curr Opin Rheumatol 20:314-9. 2008
    ..To describe current therapeutic trials with biologic agents for early rheumatoid arthritis, analyzing clinical and radiographic outcomes...
  51. doi request reprint Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies
    Hal M Hoffman
    Division of Rheumatology and Allergy Immunology, University of California at San Diego, La Jolla, CA 92093 0635, USA
    Arthritis Rheum 58:2443-52. 2008
    ....
  52. doi request reprint Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
    Robin K Dore
    Robin K Dore Inc, Tustin, CA, USA
    Ann Rheum Dis 69:872-5. 2010
    ....
  53. doi request reprint CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis
    Sanna Rosengren
    Division of Rheumatology, Department of Medicine, Allergy and Immunology, University of California at San Diego School of Medicine, 9500 Gilman Drive, Mail Code 0656, La Jolla, CA 92093 0656, USA
    Rheumatology (Oxford) 50:603-10. 2011
    ..The B-cell chemokine, CXCL13, is a proposed serum biomarker of synovitis in RA. Its behaviour in the context of B-cell depletion therapy and reconstitution was studied during treatment of RA with rituximab...
  54. doi request reprint The pathobiology of psoriatic synovium
    David L Boyle
    Rheumatology, Allergy, Immunology Division, University of California, San Diego, California 92093, USA
    Curr Opin Rheumatol 20:404-7. 2008
    ..Currently, approaches similar to those applied to rheumatoid arthritis are being applied to psoriatic arthritis synovia...
  55. doi request reprint An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
    Michael E Weinblatt
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:1303-12. 2010
    ..The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy...
  56. ncbi request reprint Rheumatic disease in the elderly: rheumatoid arthritis
    Zuhre Tutuncu
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Rheum Dis Clin North Am 33:57-70. 2007
    ..There is substantial need for improving aspects of diagnostic and therapeutic interventions that will reduce the impact of inflammatory arthritis in the growing elderly population...
  57. ncbi request reprint Biologic agents in rheumatology: safety considerations
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, The University of California, San Diego, USA
    Rheum Dis Clin North Am 32:3-10. 2006
  58. pmc Quantitative biomarker analysis of synovial gene expression by real-time PCR
    David L Boyle
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, California, USA
    Arthritis Res Ther 5:R352-60. 2003
    ..The technique can potentially be used in serial biopsy studies to provide insights into mechanism of action and therapeutic effect of new anti-inflammatory agents...
  59. ncbi request reprint Rheumatoid arthritis in dermatology
    Tissa Hata
    Department of Medicine, Division of Dermatology, University of California, San Diego School of Medicine, La Jolla, 92093 0943, USA
    Clin Dermatol 24:430-7. 2006
    ..Understanding the etiology and therapy for cutaneous manifestations of RA will help optimize patient care...
  60. ncbi request reprint Tumor necrosis factor as a therapeutic target of rheumatologic disease
    Christoph Ackermann
    University of California, Center for Innovative Therapy, Divison of Rheumatology, Allergy and Immunology, San Diego, La Jolla, CA 92093 0943, USA
    Expert Opin Ther Targets 11:1369-84. 2007
    ..In addition to the presently available TNF-alpha blockers, other agents targeting this key mediator are under study. Recent advances and future directions in anti-TNF-alpha therapy are discussed in this paper...
  61. pmc Perceptions of disease and health-related quality of life among patients with gout
    Susan J Lee
    San Diego Veterans Affairs Medical Center, San Diego, CA, USA
    Rheumatology (Oxford) 48:582-6. 2009
    ..To assess the impact of gout on health-related quality of life (HRQoL) among patients in three large US cities...
  62. ncbi request reprint Rheumatic disease in the elderly: rheumatoid arthritis
    Zuhre Tutuncu
    Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Clin Geriatr Med 21:513-25, vi. 2005
    ..There is definitely a substantial need for improving different aspects of diagnostic and therapeutic interventions that will reduce the impact of inflammatory arthritis in the growing elderly population...
  63. ncbi request reprint Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents
    Zuhre Tutuncu
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla 92093 0943, USA
    Arthritis Rheum 52:2693-6. 2005
    ....
  64. doi request reprint Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study
    Susan J Lee
    Veterans Affairs San Diego Healthcare System, and University of California, San Diego, Department of Medicine, San Diego, California, USA
    J Rheumatol 36:1611-7. 2009
    ..To determine whether these findings have altered practice patterns, we used the Consortium of Rheumatology Researchers of North America (CORRONA) registry to assess the pattern of TNF inhibitor utilization in the US over time...
  65. ncbi request reprint Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines
    Arthur F Kavanaugh
    University of California at San Diego, San Diego, California, USA
    J Rheumatol 33:1417-21. 2006
    ..We outline the specific methods and procedures used in this evidence-based, systematic review of treatments for PsA, which we hope will provide a basis for future treatment guidelines...
  66. ncbi request reprint Adverse reactions to biologic agents: focus on autoimmune disease therapies
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, CA 92093 0943, USA
    J Allergy Clin Immunol 116:900-5. 2005
    ..An understanding of the spectrum and types of reactions possible with biologic agents, as well as the mechanisms underlying such reactions, will help clinicians use them optimally...
  67. ncbi request reprint Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial
    Maria Dall'Era
    Division of Rheumatology, University of California San Francisco 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Arthritis Rheum 56:4142-50. 2007
    ..Atacicept is a TACI-Ig fusion protein that inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand...
  68. ncbi request reprint Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments
    Jeffry Bieber
    Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92037 0943, USA
    Rheum Dis Clin North Am 30:257-70, v. 2004
    ..Screening for latent TB infection with purified protein derivative is indicated for patients who are being considered for treatment; it seems to be effective in reducing the occurrence of TB in treated patients...
  69. doi request reprint Treatment of psoriatic arthritis with biological agents
    Arnold Ceponis
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, CA 92037 0943, USA
    Semin Cutan Med Surg 29:56-62. 2010
    ..Herein we review the evidence regarding the treatment of PsA arthritis with biological agents...
  70. ncbi request reprint Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, California 92093 0943, USA
    Adv Ther 23:208-17. 2006
    ..The biologic agent, anakinra, provides to patients with RA a valuable treatment option that has a positive impact on both function and quality of life...
  71. ncbi request reprint Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials
    Susan J Lee
    Division of Rheumatology, Allergy, Immunology, University of California, San Diego, California 92037 0943, USA
    J Rheumatol 32:2317-25. 2005
    ..To delineate the personal, psychosocial, and disease-related factors that may influence rheumatoid arthritis (RA) patients' decisions to participate in clinical trials...
  72. doi request reprint Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II tria
    Eva C Koffeman
    University of California, San Diego, La Jolla, CA, USA
    Arthritis Rheum 60:3207-16. 2009
    ....
  73. ncbi request reprint Current treatments for rheumatoid arthritis
    Arthur Kavanaugh
    University of California, San Diego, USA
    Am J Orthop (Belle Mead NJ) 36:4-7. 2007
  74. ncbi request reprint Economic burden of psoriatic arthritis
    Christoph Ackermann
    The Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, California 92093 0943, USA
    Pharmacoeconomics 26:121-9. 2008
    ..The notable clinical efficacy of the TNFalpha inhibitors needs to be factored into a comprehensive assessment of their value. Further analyses are needed to optimize the use of the new biologic agents in PsA...
  75. ncbi request reprint Pharmacological treatment of established rheumatoid arthritis
    Susan Jung Ah Lee
    Division of Allergy, Immunology and Rheumatology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Best Pract Res Clin Rheumatol 17:811-29. 2003
    ..The indications, efficacy and safety of these agents in clinical trials and practice are reviewed in this chapter...
  76. doi request reprint Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, CA 92093 0943, USA
    J Allergy Clin Immunol 125:S314-23. 2010
    ..These agents have the potential both to optimize outcomes through more thorough modulation of specific parts of the dysregulated immune response and to minimize toxicity compared with less specific methods of immunosuppression...
  77. ncbi request reprint Biologic therapies for the treatment of asthma
    Amy L Wagelie-Steffen
    Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0637, USA
    Clin Chest Med 27:133-47, vii. 2006
    ..This article describes several potential novel biologic therapies that have been or could be investigated...
  78. doi request reprint The clinical efficacy of tocilizumab in rheumatoid arthritis
    Maja Mircic
    The Center for Innovative Therapy, Division of Rheumatology, Allergy, Immunology, The University of California, San Diego, La Jolla, California 92093 0943, USA
    Drugs Today (Barc) 45:189-97. 2009
    ..The largest amount of data to date comes from trials of the humanized anti-IL-6 receptor antibody tocilizumab. Studies worldwide have demonstrated the clinical efficacy of this agent in patients with RA...
  79. ncbi request reprint A web-compatible instrument for measuring self-reported disease activity in arthritis
    Ninad Athale
    Health Services Research and Development, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, University of California, San Diego UCSD, California 92161, USA
    J Rheumatol 31:223-8. 2004
    ..To describe a Web-based computer health assessment survey for patients with rheumatoid arthritis (RA) and to evaluate the survey in comparison with current paper versions...
  80. ncbi request reprint The treatment of psoriatic arthritis and inflammatory spondylitis
    Hernan Castro-Rueda
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92093 0943, USA
    Curr Pain Headache Rep 12:412-7. 2008
    ..Factors such as cost-effectiveness and safety will need to be better characterized over time...
  81. ncbi request reprint 4. Autoimmunity, vasculitis, and autoantibodies
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, and the Center for Innovative Therapy, The University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    J Allergy Clin Immunol 117:S445-50. 2006
    ....
  82. ncbi request reprint GRAPPA Treatment Recommendations: An Update from the GRAPPA 2013 Annual Meeting
    Laura C Coates
    From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York and the University of California at San Diego, California, USA L C Coates, MRCP, PhD, UK National Institute for Health Research Clinical Lecturer, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds C T Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center A F Kavanaugh, MD, Professor of Medicine, University of California at San Diego
    J Rheumatol 41:1237-9. 2014
    ..We also review the numerous discussions regarding how best to finalize and publish these new guidelines in 2014. ..
  83. pmc Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial
    Dinesh Khanna
    David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
    Arthritis Rheum 60:1102-11. 2009
    ....
  84. ncbi request reprint The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis
    Sarah E Cassell
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, San Diego, California, USA
    J Rheumatol 34:123-9. 2007
    ..Beginning with NAPSI, our goal was to validate a psoriatic nail assessment tool for use in clinical trials, and investigate correlations between nail and other PsA features...
  85. ncbi request reprint A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
    J Rheumatol 32:2345-50. 2005
    ..We evaluated the safety and possible biologic effect of intradermal injections of PVAC in patients with diffuse SSc...
  86. ncbi request reprint Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal
    Michael H Weisman
    Evidence Based Medicine Working Groups in Rheumatology, Beverly Hills, CA, USA
    J Rheumatol 30:1739-47. 2003
    ..To describe and compare the relative attributes (reliability, ease of use, applicability, and relevance) of different assessment tools for economic analyses as they pertain to rheumatoid arthritis (RA) literature...
  87. ncbi request reprint Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled
    Edward C Keystone
    University of Toronto, Toronto, Ontario M5G 1X5, Canada
    Arthritis Rheum 50:1400-11. 2004
    ....
  88. ncbi request reprint The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    ..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment...
  89. ncbi request reprint Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al
    Theodore Pincus
    Arthritis Rheum 52:4044-5; author reply 4045-7. 2005
  90. ncbi request reprint Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
    ..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms...
  91. ncbi request reprint Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology
    Allan S Wiik
    Statens Serum Institut, Copenhagen, Denmark
    Arthritis Rheum 51:291-8. 2004
  92. ncbi request reprint Macromolecule tumor necrosis factor inhibitors: are more better?
    Arthur F Kavanaugh
    J Rheumatol 32:2285-7. 2005
  93. ncbi request reprint Outcome measures in psoriatic arthritis
    Dafna D Gladman
    University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto, Canada
    J Rheumatol 32:2262-9. 2005
    ..A set of domains to be included in the assessment of patients with PsA was derived, and a research agenda was developed...
  94. doi request reprint American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008
  95. ncbi request reprint Evidence-based use of rheumatologic laboratory tests
    Arthur F Kavanaugh
    Arch Intern Med 164:109. 2004